Clinical Trials Browser

Phase 2 × surufatinib × 90 days × Clear all

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma